Teva Pharmaceutical Industries (NYSE:TEVA) EVP Richard Daniell Sells 20,003 Shares of Company Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Richard Daniell sold 20,003 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $42.80, for a total value of $856,128.40. Following the sale, the executive vice president owned 55,755 shares in the company, valued at approximately $2,386,314. This trade represents a 26.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Richard Daniell also recently made the following trade(s):

• On Monday, November 9th, Richard Daniell sold 25,000 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $42.91, for a total value of $1,072,750.00.

Teva Pharmaceutical Industries Stock Up 0.7%

Shares of NYSE TEVA opened at $43.52 on Friday. The company has a 50 day simple moving average of $40.00 and a 200 day simple moving average of $35.01. The firm has a market cap of $50.72 billion, a PE ratio of 101.22, a price-to-earnings-growth ratio of 4.05 and a beta of 0.97. Teva Pharmaceutical Industries Ltd. has a 1 year low of $24.01 and a 1 year high of $44.31. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The business had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same period last year, the company earned $0.78 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current year.

Latest Teva Pharmaceutical Industries News

These are some of the TEVA news items that stood out recently:

• Positive Sentiment: At its R&D Day, Teva outlined a goal of generating $6–7 billion in innovative-medicines revenue by 2030 and shared pipeline updates, including potential first-in-class treatments for Tourette syndrome, celiac disease and intestinal scarring. The growth plan and pipeline progress could strengthen the investment case, though they remain forward-looking goals. R&D Day announcement
• Neutral Sentiment: Healthcare stocks broadly declined Wednesday afternoon, a sector headwind that may have affected trading but does not reflect Teva-specific fundamentals. Healthcare sector update
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.6 million, reducing his stake by 21.23%. EVP Richard Daniell also sold 20,003 shares and 25,000 shares in separate transactions. These sizable insider sales may raise concerns about executive confidence, although the filings do not state the reasons for the transactions. CEO SEC filing EVP SEC filing

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently added to or reduced their stakes in the stock. Root Financial Partners LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $33,000. Cornerstone Planning Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after purchasing an additional 755 shares during the period. Western Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $43,000. Sunbelt Securities Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $45,000. Finally, CX Institutional bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $54,000. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. TD Cowen raised their price target on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. HC Wainwright began coverage on Teva Pharmaceutical Industries in a report on Monday, November 2nd. They issued a “buy” rating and a $52.00 price objective for the company. Barclays increased their price objective on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a report on Thursday, October 15th. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Finally, Leerink Partners lifted their target price on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $48.15.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.